Expanded Indications for GLP-1 Receptor Agonists The 2025 American Diabetes Association (ADA) Standards of Care have broadened the use of GLP-1 receptor agonists beyond glycemic control
The DAC version produces a flatter, more constantly elevated IGF-1 curve compared to the spikier, more physiologic pattern of no-DAC
Intended to complement a balanced diet and fitness routine
This may include: IGF-1 levels Growth hormone markers Thyroid panel Metabolic markers Inflammatory markers These biomarkers help determine whether peptides such as CJC-1295, Ipamorelin, or other supportive compounds are appropriate and how they should be dosed
Neurodevelopmental disorders, like cancer, are connected to impaired chromatin remodelers, PI3K/mTOR, and PAK1-regulated MAPK
Comparison to actual GH : These underperform compared to simply taking pharmaceutical growth hormone across nearly every metric